Johnson & Johnson Innovation
- JJDC, Inc. Research
Investment Thesis
JJDC, Inc. is the corporate venture capital organization of Johnson & Johnson, part of Johnson & Johnson Innovation. It describes its job as finding transformative ideas and helping them mature into potential solutions for patients. Its strategy is explicitly aligned with the scientific goals of Johnson & Johnson, so it is a strategic investor first: it looks for science and technology that fits J&J's Innovative Medicine and MedTech priorities. The firm says all portfolio companies get the same commitment to drive science and technology towards translation for patient benefit, with access to J&J's discovery, clinical development, regulatory affairs, manufacturing and commercialization capabilities.
Stage Focus
JJDC invests across all stages. Its site lists new company creation (NewCo), seed and Series A investments in the earliest-stage startups, Series B and later investments in more mature companies, and private investments in public equity (PIPEs). Each deal is customized, with tailored roles and terms. It has a dedicated New Company Creation team that works through a discover, validate, create, launch and nurture process, often co-founding companies with specialist biotech investors (for example Aliada Therapeutics with RA Capital, and Resolve M Therapeutics with General Inception).
Check Size
JJDC does not publish a check size range. Third-party aggregators show wide variation and none is verified, so no range is recorded. JJDC reports more than $3.2B invested since 2016 and 35 initial and follow-on investments in 2025.
Lead Tendency
Both. JJDC led the $67M Series D of Ronovo Surgical in 2025 and led or co-led two rounds of HistoSonics. It co-led the EUR 85M Series B of Citryll in November 2024 alongside Forbion Ventures and Novartis Venture Fund. It also invests as a follower in syndicates, and co-creates NewCos with partners.
Recent Activity
Per the 2025 year in review (through December 2025): more than 100 active portfolio companies (excluding fund investments), 65% of active investments in US entities, 6 venture exits (IPO or M&A) in 2025, 35 initial and follow-on investments in 2025, and 3 onboardings (a license, commercial agreement or acquisition of a portfolio company by J&J). Named 2025 activity includes Prazer Therapeutics (March 2025, targeted protein degradation), Distalmotion (Q1 2025, soft tissue surgical robotics), the launch of Resolve M Therapeutics (new company creation in inflammatory disease), the Ronovo Surgical Series D, and the HistoSonics acquisition at about $2.25B (August 2025). AbbVie's $1.4B acquisition of Aliada Therapeutics closed in December 2024.
Portfolio Highlights
- HistoSonics: histotripsy platform, acquired by an investor consortium at about $2.25B in 2025; JJDC led or co-led two rounds.
- Aliada Therapeutics: blood-brain barrier delivery company co-founded with RA Capital in 2021, acquired by AbbVie for $1.4B.
- Ronovo Surgical: Shanghai-based surgical robotics, $67M Series D led by JJDC.
- Citryll: Dutch immunology biotech, EUR 85M Series B co-led in 2024.
- Distalmotion, Prazer Therapeutics, Resolve M Therapeutics, ONL Therapeutics, TECLens, Flindr Therapeutics and Accent Therapeutics also appear in JJDC announcements.
The portfolio page itself loads its company list dynamically and the page read returned no company entries, so the list above comes from the year in review and press releases linked from the firm's site. It is a partial list of a portfolio of more than 100 companies.
Team
- Chris Picariello: President, JJDC
- Asish K. Xavier: Chief Strategy & Operations Officer and Vice President, Venture Investments
- Vice Presidents, Venture Investments: Christine Brennan, V. Kadir Kadhiresan, Fiona MacLaughlin, Biren Mehta, Sanjay Mistry (New Company Creation)
- Principals: Amir Blatt, Nadiya Ishnazarova, Edna Lazar, Tamir Meiri, Nancy Ondovik, Hirak Parikh, Lior Teitelbaum, Andres Tellez (New Company Creation), Wei Wu
The site lists 16 team members in total; all are captured above.
Decision Process
A corporate venture arm with a dedicated investing team that works with J&J's scientific and business leaders. The exact approval path is not published, so the decision process is left unset.
Founder Preferences
Scientists and entrepreneurs working on translational science with a plausible fit to J&J therapeutic areas. JJDC says it understands founders' challenges because the team includes entrepreneurs and scientists with deep R&D experience. Startups often reach JJDC through the J&J Innovation Centers and the JLABS incubator network.
Geographic Focus
Global, led out of four hubs: Boston, California (San Francisco), Asia Pacific (Shanghai) and EMEA (London). 65% of active investments are in US entities; recent deals include companies in the Netherlands, China and Switzerland. J&J also runs JLABS sites in Korea, Singapore, Toronto and elsewhere.